Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

December 4, 2012

Primary Completion Date

December 26, 2014

Study Completion Date

April 10, 2018

Conditions
Crohn's Disease
Interventions
DRUG

Abrilumab

Administered by subcutaneous injection.

DRUG

Placebo

Placebo matching to abrilumab administered by subcutaneous injection

Trial Locations (84)

1050

Research Site, Vienna

1088

Research Site, Budapest

1090

Research Site, Vienna

1125

Research Site, Budapest

1200

Research Site, Brussels

2650

Research Site, Hvidovre

2730

Research Site, Herlev

2820

Research Site, Bonheiden

3000

Research Site, Leuven

3010

Research Site, Bern

3526

Research Site, Miskolc

4031

Research Site, Basel

4032

Research Site, Debrecen

4600

Research Site, Køge

5000

Research Site, Odense C

5600

Research Site, Békéscsaba

6020

Research Site, Innsbruck

7100

Research Site, Szekszárd

8000

Research Site, Århus C

8091

Research Site, Zurich

9000

Research Site, Ghent

Research Site, Aalborg

9300

Research Site, Sankt Veit an der Glan

10029

Hospital, New York

Research Site, New York

11021

Research Site, Great Neck

14033

Research Site, Caen

19104

Research Site, Philadelphia

20148

Research Site, Hamburg

27834

Research Site, Greenville

28210

Research Site, Charlotte

30342

Research Site, Atlanta

32256

Research Site, Jacksonville

32423

Research Site, Minden

32771

Research Site, Sanford

33604

Research Site, Pessac

35216

Research Site, Birmingham

36305

Research Site, Dothan

36608

Research Site, Mobile

38138

Research Site, Germantown

44060

Research Site, Mentor

48047

Research Site, Chesterfield

48109

Research Site, Ann Arbor

54511

Research Site, Vandœuvre-lès-Nancy

55905

Research Site, Rochester

59037

Research Site, Lille

60005

Research Site, Arlington Heights

65265

Research Site, Mexico

70376

Research Site, Stuttgart

73103

Research Site, Oklahoma City

75475

Research Site, Paris

75571

Research Site, Paris

80054

Research Site, Amiens

85012

Research Site, Phoenix

85395

Research Site, Goodyear

92093

Research Site, La Jolla

92110

Research Site, Clichy

98101

Research Site, Seattle

T6G 2X8

Research Site, Edmonton

V5Z 1M9

Research Site, Vancouver

R3A 1R9

Research Site, Winnipeg

P3E 1H5

Research Site, Greater Sudbury

N6A 5A5

Research Site, London

M5G 1X5

Research Site, Toronto

S7N 0W8

Research Site, Saskatoon

500 12

Research Site, Hradec Králové

140 21

Research Site, Prague

140 59

Research Site, Prague

150 06

Research Site, Prague

170 04

Research Site, Prague

401 13

Research Site, Ústí nad Labem

06202

Research Site, Nice

04105

Research Site, Leipzig

1105 AZ

Research Site, Amsterdam

4818 CK

Research Site, Breda

2333 ZA

Research Site, Leiden

6229 HX

Research Site, Maastricht

3015 CE

Research Site, Rotterdam

B18 7QH

Research Site, Birmingham

CV2 2DX

Research Site, Coventry

NW1 2BU

Research Site, London

M8 5RB

Research Site, Manchester

NR4 7UY

Research Site, Norwich

TQ2 7AA

Research Site, Torquay

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01696396 - Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter